CDMO and device maker Recipharm has joined the International Pharmaceutical Aerosol Consortium on Regulation and Science (IPAC-RS) as a member, the company announced. Recipharm will be represented on the IPAC-RS Board by Head of Commercial – Advanced Delivery Systems Peter Hirst and Director of Inhalation Sciences and Product Development Lei Mao.
According to IPAC-RS, full membership “includes innovator and generic companies that develop, manufacture or market OINDPs for local and systemic treatment of a variety of debilitating diseases such as asthma, chronic obstructive pulmonary disease and diabetes.” Associate membership in IPAC-RS is available to smaller pharma companies that make and market OINDPs, as well as companies that make devices and device components, and CROs/CDMOs that provide services for OINDPs.
Recipharm’s announcement states, “Our membership will enhance our engagement with the inhalation community by contributing to discussions on global regulations and standards relating to OINDPs (orally inhaled and nasal drug products). We will also be able to further collaborate with other industry leaders, sharing knowledge more effectively to advance research and development of inhalation technologies.”
Recipharm Head of Business Unit, Advanced Delivery Systems, Jean-François Hilaire commented, “We are delighted to have the opportunity to collaborate with the inhalation community as IPAC-RS members. Being part of this forum, enables us to contribute to the industry collective efforts in inhalation technologies and regulations.”
CDMO Lonza also joined IPAC-RS as a full member earlier this year. Other companies that have joined IPAC-RS as associate members over the past few years include RxPack, Nemera, Copley Scientific, and Proveris Scientific.
Recipharm also said that sustainability evaluator EcoVadis has awarded a gold rating for all of Recipharm’s Advanced Delivery Systems sites in the UK for 2022. In addition to the company’s sustainability efforts at its facilities, Recipharm launched services for the transition to lower-GWP MDI propellants in April 2022.
Read the Recipharm announcement.
